Accessibility Menu
Vivos logo

Vivos(OTC) RDGL

Market Cap$27.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)-100%
5 Year-47%
1 Year-35%
1 Month-8%
$0.06
+4.36%
+0.00Today
Vivos last closing stock price
MetricPriceDate
Last closeUSD 0.062026-08-14
Vivos stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.38%USD 0.052026-08-07
1 month-7.59%USD 0.062026-07-15
3 month-18.88%USD 0.072026-05-15
Year to date-20.17%USD 0.072025-12-31
1 year-35.29%USD 0.092025-08-14
3 year+2.23%USD 0.052023-08-15
5 year-47.37%USD 0.102021-08-13
Since inception-99.99%USD 416.001998-09-01

Vivos Financials at a Glance

Market Cap

$27.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$99.10K

Net Income (TTM)

-$3.60M

EPS (TTM)

-$0.01

P/E Ratio

-7.14

Dividend

$0.00

Beta (Volatility)

0.27 (Low)

Price

$0.06

Volume

131,674

Open

$0.05

Previous Close

$0.06

Daily Range

$0.05 - $0.06

52-Week Range

$0.05 - $0.12

Estimated Earnings Date

May 7, 2026

RDGL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vivos

Vivos helps treat hard-to-remove tumors in people and animals. Its main products use targeted radiation to shrink tumors with less harm to healthy tissue. Clinics and pet hospitals use these devices to offer new cancer treatment options.

Gadgets That Matter: Products and Services

  • IsoPet (100% revenue): Injectable therapy for treating solid tumors in animals, used by veterinary clinics.
  • RadioGel (0% revenue): Human-focused injectable device for cancer treatment, not yet commercialized.
  • Hydrogel Polymers: Platform for delivering drugs and therapies, sold to research institutions.
  • Duncan Chiller: Prototype lab equipment for precise cooling, not yet generating revenue.

Plot Twists: Growth and Expansion Moves

  • Rebranded from Advanced Medical Isotope to Vivos in December 2017.
  • Launched IsoPet in U.S. veterinary clinics, expanding to 17 certified sites by end of 2025.
  • Received FDA Breakthrough Device designation for RadioGel in December 2023.
  • Formed Vivos Scientific India LLP in September 2025 for manufacturing and clinical trials in India.
  • Plans to open new production facilities in Washington and India by end of 2026.

Why Vivos Is a Bit Different

Vivos specializes in targeted radiation therapies that limit damage to healthy tissue. Its animal therapy is already in use, while human products await regulatory approval. The company holds patents in over 60 countries and is expanding manufacturing to reduce supply risks.

Five Things You Need to Know

  • IsoPet made up 100% of 2025 revenue; RadioGel is pre-commercialization.
  • Revenue was $68,379 in 2025, up 144% from 2024.
  • Net loss was $3.07 million in 2025, up from $2.91 million in 2024.
  • Cash was $1.56 million at end of 2025, down from $2.21 million in 2024.
  • Auditors raised concerns about Vivos’s ability to continue as a going concern.

Bottom Line

Vivos has shifted from research to commercial animal therapies, with human products still in development. The company faces ongoing financial challenges but continues to expand its reach and product pipeline.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1

CEO

Michael K. Korenko, PhD

Website

vivosinc.com

Headquarters

Kennewick, WA 99352, US

RDGL Financials

Key Financial Metrics (TTM)

Gross Margin

-344.08%

Operating Margin

-2852.46%

Net Income Margin

-3633.27%

Return on Equity

-154.92%

Return on Capital

-178.30%

Return on Assets

-125.04%

Earnings Yield

-14.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$27.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

494.21M

Volume

131.67K

Avg. Volume

1.50M

Financials (TTM)

Gross Profit

-$340.98K

Operating Income

-$2.83M

EBITDA

-$2.34M

Operating Cash Flow

-$1.99M

Capital Expenditure

-$500.13K

Free Cash Flow

-$2.49M

Cash & ST Invst.

$2.34M

Total Debt

$103.15K

Vivos Performance Analysis

Vivos annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 36,499145.2%
20232023-12-31USD 19,500-46.6%
20242024-12-31USD 27,99543.6%
20252025-12-31USD 68,379144.3%
Vivos sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-87.5%
Q42025-12-311217.3%
Q12026-03-3145.7%
Q22026-06-300.9%
Vivos annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.01-10.3%
20232023-12-31USD -0.0111.4%
20242024-12-31USD -0.01-9.0%
20252025-12-31USD -0.01-4.2%
Vivos sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3021.4%
Q42025-12-31-118.2%
Q12026-03-31-8.3%
Q22026-06-3034.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$36.40K

+142.7%

Gross Profit

-$161.60K

-365.0%

Gross Margin

-4.44%

N/A

Market Cap

$27.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$27.18M

N/A

Employees

1

N/A

Net Income

-$830.19K

-28.6%

EBITDA

-$175.66K

+74.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.34M

-12.2%

Total Debt

$103.15K

N/A

Accounts Receivable

$15.65K

+17.9%

Inventory

$56.43K

-10.4%

Long Term Debt

$147.96K

N/A

Short Term Debt

$29.17K

N/A

Return on Assets

-1.25%

N/A

Return on Invested Capital

-99.90%

N/A

Free Cash Flow

-$758.00K

-36.9%

Operating Cash Flow

-$512.25K

+7.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MMIRFMedMira Inc.
$0.04+0.00%
SEOVFSernova Corp.
$0.07-15.92%
PETVPetVivo Holdings, Inc.
$0.68+0.37%
TLTFFTheralase Technologies Inc.
$0.13-0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About RDGL

What is the current price of Vivos?

Vivos is trading at $0.06 per share.

What is the 52-week range for Vivos?

Over the past 52 weeks, Vivos has traded between $0.05 and $0.12.

How much debt does Vivos have?

As of the most recent reporting period, Vivos reported total debt of $103.15K.

How much cash does Vivos have on hand?

Vivos reported $2.34M in cash and cash equivalents in its most recent financial results.

What is Vivos’s dividend yield?

Vivos does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services